Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, ...

Metsera, an obesity drug developer, has accepted a $10 billion acquisition offer from pharmaceutical giant Pfizer, potentially concluding a bidding war with Novo Nordisk.

Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a tumultuous bidding war with Novo Nordisk A/S ...

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Obesity drug developer Metsera said on Friday that it had accepted Pfizer's $10 billion acquisition offer, in what could ...

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...

Pfizer has submitted a sweetened bid for obesity drug developer Metsera, as its fight against rival Novo Nordisk escalates, ...

Republican Chairman Ron Johnson excoriated ranking member Richard Blumenthal in a sprawling rant that transformed the hearing ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...